Saturday 17 October 2026
Export HNGE’s income statement to Excel — free account
Hinge Health Inc.
HNGE Healthcare Health Information Services
Hinge Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $587.9 million, up 50.6% from fiscal 2024. In the quarter to June 2026, revenue grew 53.0%, EPS grew 104.2% and free cash flow grew 441.1%, each against the same quarter a year earlier.
99.16
5.80
−5.53%
Follow HNGE
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | — | — |
Altman Z-Score |
(0.64) | — | — |
P/S ratio |
4.31 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(7.69) | (0.01) | (0.87) |
P/FCF ratio |
15.33 | 10.90 | 10.90 |
P/Operating CF |
39.68 | 116.93 | 116.93 |
Beneish M-Score |
(6.18) | (3.08) | — |
P/B ratio |
14.19 | 0.00 | 0.00 |
Price to Tangible BV |
22.62 | 0.00 | 0.00 |
EV/Sales |
3.69 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
12.66 | 2.03 | 2.03 |
EV/FCF |
13.13 | 2.07 | 2.07 |
Quick Ratio |
1.19 | 2.04 | 2.55 |
Current Ratio |
1.47 | 2.34 | 2.88 |
Net Debt/EBITDA |
0.74 | (103.89) | 3.67 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.83 | 0.60 | 0.00 |
Operating CF/Net income |
(0.40) | (4.11) | 0.59 |
Capex/Depreciation |
(0.12) | (0.10) | (0.30) |
| 331.44% | 2.78% | 0.00% | |
| (59.81%) | (1.84%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(233.03%) | (3.49%) | (30.47%) |
Average Days of Receivables |
41.02 | 39.73 | 58.06 |
Research and Development Expense of Revenue |
62.62% | 25.83% | 37.60% |
Selling, General and Administrative Expense of Revenue |
109.97% | 59.16% | 73.32% |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.10 |
Share Based Compensation of Revenue |
109.38% | 0.19% | 0.56% |
Graham Net Nets |
(0.01) | (0.91) | (0.91) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(25.00%) | (24.95%) | (24.95%) |
Free Cash Flow Yield |
6.52% | 9.18% | 9.18% |
Revenue per Share |
10.77 | 28.80 | 22.49 |
Operating CF per Share |
3.14 | 3.61 | (4.91) |
Capex per Share |
(0.11) | (0.28) | (0.35) |
Free Cash Flow per Share |
3.03 | 3.34 | (5.26) |
Cash per Share |
6.67 | 34.41 | 32.52 |
Shareholders Equity per Share |
3.27 | (32.05) | (32.57) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
3.27 | (32.05) | (32.57) |
Free Cash Flow |
165.38 | 45.23 | (68.52) |
Working Capital |
171.50 | 334.15 | 345.73 |
Capital Expenditures |
(6.06) | (3.77) | (4.61) |
Net Current Asset Value |
(32.19) | (524.38) | (516.64) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
4.97 | 4.93 | 1.65 |
Cash ROIC |
30.48% | 141.33% | 10,740.44% |
Accounts Receivable Turnover |
10.83 | 8.77 | 0.00 |
Accounts Payable Turnover |
2.81 | 2.71 | 0.00 |
Inventory Turnover |
9.03 | 7.49 | 0.00 |
Average Days of Payables |
174.91 | 112.33 | 144.61 |
Days of Inventory on Hand |
47.70 | 43.85 | 49.23 |
Average Receivables |
54.28 | 44.53 | — |
Average Payables |
42.59 | 33.45 | — |
Average Inventory |
13.25 | 12.08 | — |
Average Assets |
709.01 | 647.89 | — |
Average Common Equity |
(127.95) | (429.28) | — |
Columns are period end dates